Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Cash Flow Statement
- Common-Size Income Statement
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
Operational efficiency has demonstrated a consistent decline over the observed period, characterized by an overall lengthening of the cash conversion cycle and a gradual reduction in asset turnover rates.
- Inventory and Receivables Management
- Inventory turnover exhibits a steady downward trajectory, decreasing from 2.77 in April 2022 to 2.08 by June 2026. This trend is mirrored in the average inventory processing period, which expanded from 132 days to 176 days, indicating a slowing rate of inventory movement. Simultaneously, the receivables turnover has trended downward from 6.08 to 5.14, causing the average receivable collection period to extend from 60 days to 71 days. The cumulative effect of these two metrics is an expansion of the total operating cycle from 192 days to 247 days.
- Payables and Cash Conversion Cycle
- The average payables payment period has remained volatile, fluctuating between a low of 107 days and a high of 145 days without a consistent linear trend. While payables management provides some offset to the operating cycle, it has been insufficient to counteract the slowdown in inventory and receivable turnover. As a result, the cash conversion cycle has increased significantly from 80 days in April 2022 to 140 days by June 2026, suggesting that liquidity is increasingly tied up in operational activities.
- Working Capital Utilization
- Working capital turnover exhibits extreme instability, marked by sporadic and significant spikes, most notably reaching 284.99 in June 2025 and 66.14 in December 2025. These erratic fluctuations suggest substantial volatility in the net working capital position relative to sales, contrasting with the more gradual and predictable declines observed in the individual turnover ratios.
Turnover Ratios
Average No. Days
Inventory Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of products sold | ||||||||||||||||||||||||
| Inventories | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Inventory turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Inventory turnover
= (Cost of products soldQ2 2026
+ Cost of products soldQ1 2026
+ Cost of products soldQ4 2025
+ Cost of products soldQ3 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
A consistent downward trajectory is observed in the inventory turnover ratio from April 2022 through June 2026. The ratio decreased from a high of 2.77 to 2.08, indicating a reduction in the efficiency of inventory conversion and a slower rate of stock movement over the analyzed period.
- Cost of Products Sold Analysis
- Expenditures related to the cost of products sold exhibited initial volatility, peaking at 7,919 million USD in July 2022 before declining to a low of 6,462 million USD by July 2023. Following this trough, a steady recovery is observed, with costs rising to 8,051 million USD by June 2026. This suggests a gradual increase in production volume or rising input costs over the latter half of the period.
- Inventory Level Trends
- Inventory holdings demonstrate a general upward trend, rising from 10,990 million USD in April 2022 to 15,144 million USD by June 2026. Although a temporary contraction occurred in late 2023, reaching a low of 11,181 million USD in December, a sustained accumulation of stock began in early 2024. The growth in inventory assets has significantly outpaced the growth in the cost of products sold during the final two years of the period.
- Inventory Turnover Ratio Interpretation
- The turnover ratio experienced a persistent decline, falling below the 2.30 threshold in early 2023 and continuing to erode to a final value of 2.08. This compression indicates that goods are remaining in inventory for longer durations. The divergence between rising inventory levels and more modest growth in the cost of products sold identifies the primary driver of this efficiency loss, suggesting potential overstocking or a shift in demand dynamics.
Receivables Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Sales to customers | ||||||||||||||||||||||||
| Accounts receivable, trade, less allowances | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Receivables turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Receivables turnover
= (Sales to customersQ2 2026
+ Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025)
÷ Accounts receivable, trade, less allowances
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analyzed period is characterized by a gradual decline in receivables turnover efficiency, suggesting a lengthening of the average collection cycle. While sales volumes showed a recovery and eventual growth trend toward the end of the period, the balance of trade receivables increased at a rate that outpaced revenue growth, resulting in a compressed turnover ratio.
- Sales Trends
- Sales to customers experienced a period of volatility, with a notable dip throughout 2023, reaching a low of 20,894 million USD in April 2023. Following this trough, a consistent upward trajectory was observed from 2024 through June 2026, where sales peaked at 25,310 million USD.
- Accounts Receivable Patterns
- Trade receivables remained relatively stable between 14,798 million USD and 16,777 million USD from April 2022 through December 2023. However, starting in early 2025, a significant increase in outstanding receivables occurred, with the balance rising to 19,046 million USD by June 2026. This increase indicates a higher accumulation of credit extended to customers relative to previous years.
- Receivables Turnover Efficiency
- The receivables turnover ratio exhibited a general downward trend, starting at 6.08 in April 2022 and ending at 5.14 in June 2026. A period of relative stability was maintained around the 5.7 to 5.9 range through 2023, but the ratio experienced a more pronounced decline starting in 2024, hitting a period low of 5.08 in June 2025. The consistent decrease in this ratio reflects a reduction in the frequency with which the company collects its average receivables balance during each quarter.
Payables Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Cost of products sold | ||||||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Payables turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Payables turnover
= (Cost of products soldQ2 2026
+ Cost of products soldQ1 2026
+ Cost of products soldQ4 2025
+ Cost of products soldQ3 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a period of moderate volatility in payables management, characterized by cyclical fluctuations in the payables turnover ratio. The ratio generally oscillates between a low of 2.52 and a high of 3.41, reflecting varying efficiencies in the settlement of supplier obligations relative to the cost of products sold.
- Cost of Products Sold Trends
- Expenditures for products sold demonstrated a fluctuating trajectory, beginning at 7,598 million USD in April 2022 and reaching a trough of 6,462 million USD by July 2023. Following this decline, a consistent upward trend is observed from December 2023 through March 2026, where costs peaked at 8,106 million USD before slightly moderating to 8,051 million USD by June 2026.
- Accounts Payable Dynamics
- Accounts payable balances exhibit significant variance, with recurring peaks occurring at the end of calendar years. Notable spikes are observed in December 2022 (11,703 million USD) and December 2025 (11,991 million USD). Conversely, the lowest levels of liabilities were recorded in October 2023 (8,355 million USD) and March 2024 (8,174 million USD), suggesting periods of aggressive settlement or reduced procurement volumes.
- Payables Turnover Analysis
- The payables turnover ratio shows a distinct pattern of year-end deceleration. A recurring decline in the ratio is evident every December, with the lowest values recorded in December 2025 (2.52) and December 2024 (2.66). This indicates a trend of extending payment terms or accumulating larger payables balances at the close of the fiscal year. Efficiency peaks are observed more frequently in the first and third quarters, reaching a maximum of 3.41 in June 2026, which suggests a more rapid conversion of payables into costs of products sold during these periods.
Overall, the relationship between the cost of products sold and accounts payable suggests a strategic or seasonal approach to liquidity management. The inverse correlation between the spikes in accounts payable and the dips in the turnover ratio confirms that the company's short-term operating efficiency is heavily influenced by year-end liability accumulation.
Working Capital Turnover
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||
| Less: Current liabilities | ||||||||||||||||||||||||
| Working capital | ||||||||||||||||||||||||
| Sales to customers | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Working capital turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Working capital turnover
= (Sales to customersQ2 2026
+ Sales to customersQ1 2026
+ Sales to customersQ4 2025
+ Sales to customersQ3 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of operating activity reveals a significant divergence between the stability of revenue generation and the volatility of working capital management over the observed period. While sales to customers remained relatively consistent, working capital experienced extreme fluctuations, leading to erratic swings in the working capital turnover ratio.
- Working Capital Trends
- Working capital exhibited substantial volatility, characterized by sharp contractions and expansions. Initial levels remained high through much of 2022, before plummeting to a negative value of -508 million by December 31, 2022. Subsequent periods showed inconsistent recovery, with a peak of 14,648 million in December 2024, followed by a rapid decline to 318 million by June 2025. This pattern suggests aggressive adjustments in short-term asset and liability management.
- Sales Performance
- Revenue from sales to customers demonstrated remarkable stability, generally fluctuating within a narrow band between 20,894 million and 25,310 million. The absence of significant volatility in sales indicates that the dramatic changes observed in the turnover ratio are driven entirely by balance sheet fluctuations rather than operational growth or decline in market demand.
- Working Capital Turnover Interpretation
- The working capital turnover ratio displayed extreme variance due to the diminishing denominator of working capital. In early 2022, the ratio was stable between 4.88 and 5.57. However, as working capital decreased, the ratio spiked mathematically, reaching an anomalous peak of 284.99 in June 2025. Such high ratios typically indicate that the company is operating with minimal net working capital, which may increase liquidity risk despite the appearance of high efficiency. Toward the end of the period, the ratio stabilized at a higher plateau, ranging between 20.07 and 66.14, reflecting a sustained shift toward a leaner working capital structure compared to 2022 levels.
Average Inventory Processing Period
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Inventory turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average inventory processing period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
An analysis of the operating activity ratios reveals a consistent decline in inventory management efficiency over the period from April 2022 to June 2026. There is a clear inverse correlation between the inventory turnover ratio and the average inventory processing period, characterized by a steady increase in the time required to convert inventory into sales.
- Inventory Turnover Trend
- The inventory turnover ratio exhibits a long-term downward trajectory, moving from a high of 2.77 in April 2022 to a low of 2.08 by June 2026. Although temporary improvements are observed—specifically in October 2023 (2.46) and December 2024 (2.21)—these spikes were short-lived and failed to reverse the broader trend of slowing inventory replacement.
- Average Inventory Processing Period Analysis
- The average inventory processing period increased from 132 days in April 2022 to 176 days by June 2026. A notable acceleration in this period occurred between December 2022 (147 days) and July 2023 (164 days). From 2024 onwards, the processing period remained elevated, fluctuating within a range of 163 to 176 days, signaling a structural shift in inventory holding durations.
- Operational Implications
- The expansion of the processing period by 44 days over the analyzed timeframe suggests a reduction in operational velocity. The data indicates that inventory is remaining on hand longer, which may be attributed to increased safety stock levels, a slowdown in demand, or inefficiencies in the supply chain. This trend reflects a decrease in short-term asset liquidity as a larger portion of capital remains tied up in inventory for extended durations.
Average Receivable Collection Period
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Receivables turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average receivable collection period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a gradual decline in the efficiency of receivables management between April 2022 and June 2026. A consistent inverse relationship is observed between the receivables turnover ratio and the average collection period, characterized by a downward trend in turnover and a corresponding increase in the number of days required to collect outstanding payments.
- Receivables Turnover Trend
- The receivables turnover ratio experienced a steady contraction over the observed period. Starting at a peak of 6.08 in April 2022, the ratio generally trended lower, reaching its lowest point of 5.08 in June 2025. While some periodic recoveries occurred—most notably a rise to 5.98 in December 2024—the ratio concluded the period at 5.14 in June 2026, representing a clear reduction in the frequency with which accounts receivable are converted into cash.
- Average Receivable Collection Period Analysis
- The time required to collect receivables shifted from a baseline of 60 days in early 2022 to a high of 72 days by June 2025. The collection period remained relatively stable around 60 to 62 days throughout 2022 but began to exhibit upward pressure in 2023 and 2024. Despite a temporary improvement to 61 days in December 2024, the period extended significantly thereafter, ending at 71 days in June 2026.
- Operational Insights and Volatility
- The data suggests a slowing of the cash conversion cycle related to receivables. The transition from a 60-day collection average to a 71-day average indicates that capital is tied up in receivables for approximately 11 days longer than at the start of the analysis. The most significant period of deterioration occurred between December 2024 and June 2025, where the collection period jumped from 61 to 72 days, signaling a potential shift in credit terms or a decrease in customer payment velocity during that window.
Operating Cycle
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Operating cycle1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibits a sustained upward trajectory over the analyzed period, expanding from 192 days in April 2022 to 247 days by June 2026. This progression indicates a significant lengthening of the time required to convert initial inventory investments into cash, signaling a decrease in short-term operational efficiency regarding asset turnover.
- Average Inventory Processing Period
- A consistent increase is observed in the duration of inventory processing, which rose from 132 days at the start of the period to 176 days by the end. A period of rapid escalation occurred between December 2022 and July 2023, where the period grew from 147 to 164 days. The trend remained generally positive, with a peak of 176 days reached in September 2025 and maintained through June 2026, suggesting a systemic slowing in inventory turnover.
- Average Receivable Collection Period
- The collection period for receivables shows relative stability compared to inventory processing but still reflects a marginal upward trend, increasing from 60 days to 71 days. Fluctuations are present, with a notable peak of 72 days in June 2025 and a brief dip to 61 days in December 2024. Overall, the increasing trend suggests a slight deceleration in the efficiency of credit collection processes.
- Operating Cycle Synthesis
- The expansion of the overall operating cycle is primarily driven by the growth in the average inventory processing period. While the receivable collection period contributed to the increase, the inventory component represents the dominant factor in the shift from a 192-day cycle to a 247-day cycle. The most pronounced expansions in the cycle occurred during mid-2023 and mid-2025, correlating with peak values in both inventory and receivable metrics.
Average Payables Payment Period
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Payables turnover | ||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average payables payment period1 | ||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a cyclical pattern in the management of accounts payable, characterized by recurring fluctuations in both the payables turnover ratio and the average payables payment period.
- Average Payables Payment Period Trends
- A consistent seasonal trend is observed, with payment durations peaking during the final quarter of each calendar year. Specifically, the period extended to 137 days in December 2022, 132 days in December 2023, 137 days in December 2024, and reached a peak of 145 days in December 2025. These peaks are typically followed by a contraction in the payment period during the subsequent quarters. The most recent data point for June 28, 2026, shows a reduction to 107 days, the lowest value in the analyzed period.
- Payables Turnover Ratio Analysis
- The turnover ratio exhibits an inverse correlation with the payment period, oscillating between a minimum of 2.52 in December 2025 and a maximum of 3.41 in June 2026. The ratio generally declines toward the end of the year, indicating a slower frequency of supplier payments and a corresponding increase in the average time taken to settle obligations.
- Operational Liquidity Insights
- The recurring year-end extension of the payment period suggests a strategic management of working capital or the utilization of favorable supplier credit terms to optimize cash flow at the close of the fiscal year. The transition from December 2025 to June 2026 represents the most significant shift in the series, moving from the longest payment duration (145 days) to the shortest (107 days), which corresponds with the highest recorded turnover ratio of 3.41.
Cash Conversion Cycle
| Jun 28, 2026 | Mar 29, 2026 | Dec 28, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||
| Average payables payment period | ||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Cash conversion cycle1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a pronounced upward trend over the analyzed period, indicating a lengthening of the time required to convert operational inputs into cash flows. Starting at 80 days in April 2022, the cycle experienced several fluctuations before reaching a peak of 140 days by June 2026. This expansion suggests a decline in overall working capital efficiency.
- Average Inventory Processing Period
- A consistent and significant increase in the inventory processing period is observed. The duration rose from 132 days in April 2022 to 176 days by June 2026. This steady climb indicates a slowing of inventory turnover, which serves as the primary driver for the expansion of the overall cash conversion cycle.
- Average Receivable Collection Period
- The period for collecting receivables remained relatively stable compared to inventory, though a gradual upward drift is evident. Collection times moved from 60 days in early 2022 to 71 days by June 2026. While less volatile than other metrics, the peak of 72 days in June 2025 highlights a slight degradation in the efficiency of credit and collection processes.
- Average Payables Payment Period
- The payables payment period demonstrates significant volatility and apparent seasonality. Periodic spikes are observed at year-end, reaching 137 days in December 2022 and December 2024, and a peak of 145 days in December 2025. These peaks typically provided temporary relief to the cash conversion cycle, though the period contracted to 107 days by June 2026, further contributing to the rise in the total cycle duration.
- Cash Conversion Cycle Synthesis
- The deterioration of the cash conversion cycle is primarily attributed to the substantial increase in inventory holding times, which was not sufficiently offset by the management of payables. The cycle remained below 100 days through late 2022 but transitioned to a higher baseline starting in 2023. The final surge to 140 days in June 2026 coincides with a simultaneous peak in inventory processing and a sharp reduction in the payables payment period.